Article
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
The Lancet. Oncology - 1 Oct 2018
Dummer Reinhard, Ascierto Paolo A, Gogas Helen J, Arance Ana, Mandala Mario, Liszkay Gabriella, Garbe Claus, Schadendorf Dirk, Krajsova Ivana, Gutzmer Ralf, Chiarion Sileni Vanna, Dutriaux Caroline, de Groot Jan Willem B, Yamazaki Naoya, Loquai Carmen, Moutouh-de Parseval Laure A, Pickard Michael D, Sandor Victor, Robert Caroline, Flaherty Keith T
Abstract excerpt
BACKGROUND: Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAFV600-mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoint of overall survival. METHODS: COLUMBUS was a two-part, randomised, open-label, phase 3 study done at 162 hospitals in 28 countries. Eligible patients were aged at least 18...
Topics
Join the communities discussing this publication.